LSE Equity Snapshot
FARN Weekly Equity Report
Faron Pharmaceuticals Oy
What the company does
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company's lead product candidate is Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-associated macrophages and converts the highly immunosuppressive M2-like macrophages to a pro-inflammatory state to promote immune activation. It is also developing bexmarilimab for the treatment of hematological and solid tumor cancers; and in combination with care therapies, azacitidine, and other hypomethylating agents in relapsed/refractory myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia. In addition, the company develops receptors involved in regulation of immune response …
What the weekly tape is saying
FARN closed the latest completed week at 45.00 GBP. The 4-week return is 3.4% and the 12-week return is 1.1%. Trend Signal is inactive, Market Dynamics is 0.34. Setup signature: Risk-first tape with a 25/100 composite read.
A compressed read of the whole setup
The radar blends trend persistence, momentum, Market Dynamics, Relative Strength, volume confirmation, and risk control into one weekly cockpit.
Scoreboard
16-week signal tape
Price, Trend Line, and Fair Value
Weekly price context with the latest close, trend position, Fair Value gap, drawdown, and 52-week range location.
52-week price path
Price map
- Trend Line
- 99.15 GBP
- Vs Trend Line
- -54.6%
- Fair Value
- 189.7 GBP
- Vs Fair Value
- -76.3%
- 52W High
- 240.0 GBP
- 52W Low
- 38.00 GBP
- Drawdown
- -81.2%
- Range Position
- 3.5%
Returns and trend persistence
Return windows separate the latest week from short-term and medium-term follow-through.
Return windows
Trend read
- Active Streak
- 0 weeks
- 52W Active Weeks
- 11
- 52W Active Breadth
- 21.2%
- Sector Scope
- GB Healthcare
- Sector Rank
- 45 of 78
- Sector Percentile
- 42.9%
Sector and industry pulse
Peer breadth helps separate a stock-specific move from a broader group rotation.
GB Healthcare
- Tracked Peers
- 78
- 4W Rank
- 23 of 78
- Avg 1W
- -2.0%
- Avg 4W
- -0.2%
- Trend Breadth
- 38.5%
- Positive MD
- 55.1%
GB Biotechnology
- Tracked Peers
- 29
- 4W Rank
- 9 of 29
- Avg 1W
- -3.7%
- Avg 4W
- -0.5%
- Trend Breadth
- 37.9%
- Positive RS
- 34.5%
Pressure, Relative Strength, and expectation
Market Dynamics and Relative Strength show whether buying pressure and relative leadership are confirming the price move.
Dynamics path
Signal state
- Market Dynamics
- 0.34
- 4W MD Change
- 144.2%
- Relative Strength
- -70.77
- 4W RS Change
- 4.4%
- Expectation
- Undecided
- Probability
- 45.39%
Participation and confirmation
Volume tells us whether the latest weekly move is being confirmed by unusual participation.
52-week volume profile
Volume map
- Latest Volume
- 159.8K
- 13W Average
- 588.0K
- 52W Average
- 381.4K
- Vs 13W
- 0.3x
- Vs 52W
- 0.4x
Volatility, downside weeks, and return shape
A compact risk profile shows whether the move is steady, volatile, or being driven by sharp one-week jumps.
26-week return distribution
Risk map
- 13W Volatility
- 6.0%
- 52W Volatility
- 11.3%
- Upside Weeks
- 17
- Downside Weeks
- 31
- Downside Breadth
- 59.6%
- Avg Gain / Loss
- 6.4% / -7.0%
Classification, opportunities, risks, and watch points
Top-level read across company classification, constructive evidence, caution points, and the next things that matter.
Classification
- Exchange
- LSE
- Country
- GB
- Sector
- Healthcare
- Industry
- Biotechnology
- Currency
- GBP
- Market Cap
- 93.8M
Opportunity signals
- Market Dynamics is positive on the latest completed week.
Risk signals
- Trend Signal is inactive, so price action has not confirmed a constructive regime.
- Price is below the Trend Line, which keeps downside pressure in focus.
- Price is below Fair Value, so the market is still discounting the latest tape.
- The share remains more than 20% below its 52-week high.
Watch next
- Trend Line remains the key weekly regime level.
- Market Dynamics is the pressure gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Recent completed weeks
The latest weekly rows behind the report snapshot.
| Week | Close | Return | Trend | Fair Value | MD | RS | Volume | Signal |
|---|---|---|---|---|---|---|---|---|
| 12 Jun 2026 | 45.00 GBP | -2.2% | 99.15 GBP | 189.7 GBP | 0.34 | -70.77 | 159.8K | Off |
| 5 Jun 2026 | 46.00 GBP | -2.1% | 103.9 GBP | 191.1 GBP | 0.16 | -70.65 | 309.5K | Off |
| 29 May 2026 | 47.00 GBP | 13.3% | 108.8 GBP | 192.5 GBP | -0.08 | -70.87 | 493.9K | Off |
| 22 May 2026 | 41.50 GBP | -4.6% | 114.0 GBP | 193.9 GBP | -0.43 | -75.20 | 407.6K | Off |
| 15 May 2026 | 43.50 GBP | 3.6% | 118.8 GBP | 195.5 GBP | -0.78 | -74.03 | 206.2K | Off |
| 8 May 2026 | 42.00 GBP | 1.2% | 123.3 GBP | 197.1 GBP | -0.96 | -75.60 | 511.3K | Off |
| 1 May 2026 | 41.50 GBP | 1.2% | 127.9 GBP | 198.7 GBP | -1.01 | -76.80 | 416.2K | Off |
| 24 Apr 2026 | 41.00 GBP | -6.8% | 132.6 GBP | 200.5 GBP | -1.05 | -77.60 | 425.4K | Off |
| 17 Apr 2026 | 44.00 GBP | 1.1% | 137.4 GBP | 202.3 GBP | -1.08 | -77.11 | 741.6K | Off |
| 10 Apr 2026 | 43.50 GBP | -9.4% | 142.1 GBP | 204.0 GBP | -1.11 | -77.73 | 2.6M | Off |
| 3 Apr 2026 | 48.00 GBP | 10.3% | 146.9 GBP | 205.8 GBP | -1.24 | -75.69 | 388.4K | Off |
| 27 Mar 2026 | 43.50 GBP | -2.2% | 151.8 GBP | 207.4 GBP | -1.31 | -77.43 | 355.4K | Off |
| 20 Mar 2026 | 44.50 GBP | -2.0% | 157.1 GBP | 209.1 GBP | -1.35 | -77.24 | 650.3K | Off |
| 13 Mar 2026 | 45.40 GBP | -7.7% | 163.1 GBP | 210.9 GBP | -1.34 | -77.93 | 709.7K | Off |